2016Dermatology TimesRequires access

Isotretinoin: Time to reconsider blood test best practices

Randy Dotinga

Open publisher page 0 citations

Abstract

While oral isotretinoin has been associated with various side effects and routine blood tests have been recommended, evidence points to inconsistencies in monitoring practices. Many physicians also are questioning whether the effort has value.

About this research paper

What this paper is about

While oral isotretinoin has been associated with various side effects and routine blood tests have been recommended, evidence points to inconsistencies in monitoring practices. Many physicians also are questioning whether the effort has value.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

While oral isotretinoin has been associated with various side effects and routine blood tests have been recommended, evidence points to inconsistencies in monitoring practices. Many physicians also are questioning whether the effort has value.

Key concepts: Medicine, Isotretinoin, Blood test, Dermatology, Test (biology), Clinical pharmacology, Intensive care medicine, Family medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
Isotretinoin: Time to reconsider blood test best practices — Research Paper | ScholarLens